It was demonstrated that treatment with osimertinib could promote the formation and release of wild type EGFR (wtEGFR)-harbouring exosomes in wtEGFR-expressing NSCLC cells by upregulating a Rab GTPase (RAB17), and exosome-mediated intercellular transfer of wtEGFR further triggered osimertinib resistance in mutEGFR NSCLC through activating downstream PI3K/AKT and MAPK signaling pathways [383]. This evidence concerns the gene RAB17 and non-small cell lung carcinoma.